№ lp_1_2_62864
File format: docx Character count: 62975 File size: 324 KB
This document is an application for the inclusion of Fluad (aTIV) and Fluad Quad (aQIV) vaccines in the National Immunisation Program, outlining clinical claims and economic analyses to support their listing for elderly vaccination against influenza in Australia.
Year: 2019
Region / City: Australia
Topic: Influenza Vaccination
Document Type: Application for Immunization Program Listing
Organization / Institution: Seqirus (Australia) Pty Ltd
Author: Seqirus (Australia) Pty Ltd
Target Audience: Health policymakers, healthcare providers
Period of Validity: Ongoing
Approval Date: 2019
Amendment Date: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Destination Vaccination [Retailer Name] − Adults, the Flu, and Quadrivalent Influenza Vaccine
Year: 2014-2015
Region / City: United States
Topic: Influenza Vaccination
Document Type: Informational Guide
Organization / Institution: Centers for Disease Control and Prevention (CDC)
Author: [xxx]
Target Audience: Pharmacists, Healthcare Providers, Retailers
Period of Validity: Current influenza season
Approval Date: Not specified
Modification Date: Not specified
QUADRIVALENT INFLUENZA VACCINE, Pre-filled syringe, 0.5mL, Afluria® Quad, Seqirus
Year: 2016
Region / City: Australia
Topic: Influenza Vaccination
Document Type: Regulatory Submission
Organ / Institution: PBAC, TGA
Author: Seqirus
Target Audience: Healthcare professionals, regulatory bodies
Period of Validity: Not specified
Approval Date: Not specified
Amendment Date: Not specified
Clinical Trials: Yes
Main Comparator: Fluarix® Tetra
Outcome: Non-inferiority of Afluria® Quad
Context: The document outlines the submission and evaluation of Afluria® Quad for listing on the National Immunisation Program in Australia, comparing it with existing vaccines.
Grippol® Quadrivalent Patient Information Leaflet
Year: 2026
Region / City: Russian Federation
Type: Patient information leaflet
Product: Grippol® Quadrivalent
Therapeutic group: Vaccine against influenza (inactivated) with adjuvant
Dosage form: Solution for intramuscular and subcutaneous injection
Active ingredients: Influenza virus antigens A(H1N1), A(H3N2), B Yamagata, B Victoria, Azoximer bromide
Indications: Influenza prophylaxis for children over 6 years, adolescents, adults under 60 years, high-risk and occupational groups
Contraindications: Allergy to chicken proteins or vaccine components, age under 6, pregnancy (for preservative-containing vaccine), acute illness
Administration: Intramuscular or deep subcutaneous injection, 0.5 ml per dose, annual vaccination
Storage conditions: 2–8 °C, protect from contamination, follow aseptic rules
Regulatory status: Marketing authorization in Russia
Topics: ADJUVANTED Fluad Quadrivalent